AAV vector based gene therapy (REGENXBIO)

N/A

Report date: 2025/01/26 15:58:17

Base Information

Drug NameAAV vector based gene therapy (REGENXBIO)
Drug Alias NameAAV2/sGFP-TatNrf2mer (University of Florida)gene encoding antibody targeting plama kallikrein (REGENXBIO)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionPlasma kallikrein modulators
TargetsPlasma kallikrein
Therapy Area/IndicationsAngioedemas, Hereditary
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRegenxbio Inc
China Registration ClassN/A

Develop Information

Active CompaniesRegenxbio Inc
Inactive CompaniesN/A
Active IndicationsAngioedemas, Hereditary
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A